|GRANTWAY
EN

NIA Renewal and Revision Cooperative Agreements in AD/ADRD Research (U54 Clinical Trial Optional)

National Institutes of Health

Share
Favorite
Feedback
Summary
-
17 October 2024
-
-
-
For profit
Not for profit (incl. NGOs)
Public sector
R&D and Higher Education
United States of America
Health, Justice and Social Welfare Research, Development and Innovation
Overview

This Funding Opportunity Announcement (FOA) allows for renewal and competing revision applications, and their resubmissions, for funded U54Specialized Centercooperative agreements thatsupportlarge-scale, complex research projects with multiple highly integrated components focused onacommon research question relevant to Alzheimers disease (AD) andAlzheimers disease-related dementias (ADRD).It is anticipated that such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium ofinstitutions,andwill address one or moreAD/ADRD implementation research milestonessupporting theresearch goals of theNational Plan to Address Alzheimers and Related Dementias.

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Learn more or apply
All information about this funding has been collected from and belongs to the funding organization
20 April 2023